Kalbio Global Medika (KGM) is a pioneering biopharmaceutical brand in Indonesia, established in 2014 and officially inaugurated in 2018 by President Joko Widodo. As a subsidiary of PT Kalbe Farma, Tbk., the leading healthcare provider in Indonesia and Southeast Asia, KGM is positioned as a key player in the biotechnology industry.

KGM is part of the PT Kalbe-Genexine Biologics (KGbio) Group, a clinical-stage biotechnology company focused on bringing biologics medical innovation to markets outside of the US, Canada, Western Europe, and China.

As a cGMP contract development and manufacturing organization (CDMO), KGM offers a wide range of services, including process development and optimization, protein and monoclonal antibody manufacturing, and full support services from cell storage to final packaging. Additionally, KGM provides QC toll-in services for biologics.

With an emphasis on product quality and sustainability, KGM is dedicated to improving health through the production of high-quality and accessible biopharmaceutical products. Their current pipeline includes both biosimilars and novel biologics. KGM also prioritizes local manufacturing content in medicinal raw materials and biological pharmaceutical products, supporting the Indonesian government's initiatives.

By leveraging their CMC and scale-up capabilities and state-of-the-art facility, KGM strives to be the best CMO and CDMO in the region, driven by quality, innovation, and operational excellence.